CZC-25146

Overview

CZC-25146 is a potent and orally active LRRK2 inhibitor with IC 50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2 , respectively. CZC-25146 inhibits PLK4 , GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro . CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > TNK1 | Products > Signaling Pathways > LRRK2

Product Information

• Catalog No.: HY-15800A
• CAS No.: 1191911-26-8
• Molecular Formula: C22H25FN6O4S
• Molecular Weight: 488.54
• Purity: 98.05%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.12 mM); Clear solution
• Availability: In-stock

Source

Original product source